JP2009535036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535036A5 JP2009535036A5 JP2009507945A JP2009507945A JP2009535036A5 JP 2009535036 A5 JP2009535036 A5 JP 2009535036A5 JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009507945 A JP2009507945 A JP 2009507945A JP 2009535036 A5 JP2009535036 A5 JP 2009535036A5
- Authority
- JP
- Japan
- Prior art keywords
- time point
- gene expression
- level
- hcv
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940122604 HCV protease inhibitor Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79552006P | 2006-04-26 | 2006-04-26 | |
| PCT/US2007/067421 WO2007127801A2 (en) | 2006-04-26 | 2007-04-25 | Hepatitis c virus infection biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535036A JP2009535036A (ja) | 2009-10-01 |
| JP2009535036A5 true JP2009535036A5 (enExample) | 2010-06-17 |
Family
ID=38656353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507945A Pending JP2009535036A (ja) | 2006-04-26 | 2007-04-25 | Ｃ型肝炎ウイルス感染症のバイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100028874A1 (enExample) |
| EP (1) | EP2016195A4 (enExample) |
| JP (1) | JP2009535036A (enExample) |
| KR (1) | KR20090023360A (enExample) |
| CN (1) | CN101479389A (enExample) |
| AU (1) | AU2007244824A1 (enExample) |
| CA (1) | CA2650616A1 (enExample) |
| IL (1) | IL194920A0 (enExample) |
| MX (1) | MX2008013796A (enExample) |
| NO (1) | NO20084954L (enExample) |
| NZ (1) | NZ573052A (enExample) |
| RU (1) | RU2008146518A (enExample) |
| WO (1) | WO2007127801A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| JP2009178057A (ja) * | 2008-01-29 | 2009-08-13 | Miyazakiken Sangyo Shien Zaidan | インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット |
| EP2328656A1 (en) * | 2008-09-24 | 2011-06-08 | Vertex Pharmaceuticals Incorporated | Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis " |
| US9709565B2 (en) | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| CN102178927A (zh) * | 2011-03-01 | 2011-09-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途 |
| CN102323426A (zh) * | 2011-08-08 | 2012-01-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 用于诊断或筛查丙型肝炎病毒感染的试剂 |
| US9726668B2 (en) | 2012-02-09 | 2017-08-08 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2015157639A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| CA3190715A1 (en) | 2014-08-14 | 2016-02-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| CN107427552B (zh) * | 2014-08-22 | 2022-12-20 | 广州英恩迈生物医药科技有限公司 | 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物 |
| WO2016059636A1 (en) | 2014-10-14 | 2016-04-21 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| CN107209184B (zh) | 2014-12-11 | 2020-04-24 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| CN108699609A (zh) | 2016-03-03 | 2018-10-23 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
| WO2017149548A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| AU2017278254A1 (en) | 2016-06-07 | 2018-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosis of bacterial and viral infections |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| EP4141448A1 (en) | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| EP3519834A4 (en) | 2016-09-29 | 2020-06-17 | MeMed Diagnostics Ltd. | RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| CN108379584B (zh) * | 2018-04-12 | 2020-08-11 | 上海交复生物医药科技有限公司 | RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性 |
| CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
| KR102289533B1 (ko) * | 2019-08-19 | 2021-08-17 | 주식회사 테라젠바이오 | 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램 |
| CN111333710B (zh) * | 2020-03-04 | 2021-12-03 | 暨南大学 | C20orf24蛋白缺失突变体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407587A (pt) * | 2003-02-18 | 2006-02-14 | Pfizer | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam |
| US20050282179A1 (en) * | 2003-12-05 | 2005-12-22 | Applera Corporation | Biomarkers for interferon-alpha response in hepatitis C virus infected patients |
| EP1831403A4 (en) * | 2004-12-30 | 2010-04-28 | Univ Louisville Res Found | GENETIC MARKERS OF SCHIZOPHRENIA |
-
2007
- 2007-04-25 RU RU2008146518/13A patent/RU2008146518A/ru not_active Application Discontinuation
- 2007-04-25 WO PCT/US2007/067421 patent/WO2007127801A2/en not_active Ceased
- 2007-04-25 JP JP2009507945A patent/JP2009535036A/ja active Pending
- 2007-04-25 MX MX2008013796A patent/MX2008013796A/es not_active Application Discontinuation
- 2007-04-25 AU AU2007244824A patent/AU2007244824A1/en not_active Abandoned
- 2007-04-25 CA CA002650616A patent/CA2650616A1/en not_active Abandoned
- 2007-04-25 CN CNA200780023526XA patent/CN101479389A/zh active Pending
- 2007-04-25 NZ NZ573052A patent/NZ573052A/en not_active IP Right Cessation
- 2007-04-25 KR KR1020087028981A patent/KR20090023360A/ko not_active Ceased
- 2007-04-25 EP EP07761284A patent/EP2016195A4/en not_active Withdrawn
- 2007-04-25 US US12/298,353 patent/US20100028874A1/en not_active Abandoned
-
2008
- 2008-10-26 IL IL194920A patent/IL194920A0/en unknown
- 2008-11-25 NO NO20084954A patent/NO20084954L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535036A5 (enExample) | ||
| ES2361458T5 (es) | Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana | |
| JP2012513479A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2009511595A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2007504269A5 (enExample) | ||
| JP2011511804A5 (enExample) | ||
| JP2009526751A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| JP2004525179A5 (enExample) | ||
| CA2515293A1 (en) | Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage | |
| EA200201263A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ | |
| JP2005532372A5 (enExample) | ||
| JP2009517473A5 (enExample) | ||
| JP2017515854A5 (enExample) | ||
| JP2010520200A5 (enExample) | ||
| RU2010153688A (ru) | Режим дозирования телапревира | |
| CY1110182T1 (el) | Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων | |
| JP2020529995A5 (enExample) | ||
| DE602005025347D1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| JP2009503045A5 (enExample) | ||
| JP2009500045A5 (enExample) | ||
| RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten |